Search

Thiabendazole

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.

Manitimus

FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.

PG-530742

PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. … By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression.

Diosmin

It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. … Chronic venous insufficiency is a common condition the western population.

Vapitadine

Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis … An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.

Amorolfine

It is not approved for the treatment of onychomycosis in the United States or Canada. … It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries

DA-697b

DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

Pivmecillinam

It is active against gram-negative organisms and used as for amdinocillin. [PubChem] … Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.

Latiglutenase

SNX-5422

As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers. … SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor.